抗肺纤维化药物治疗研究进展  

The Advances of the Drug Therapy for Pulmonary Fibrosis

作　　者：崔冰[1] 胡卓伟[1] 

机构地区：[1]中国医学科学院北京协和医学院药物研究所,北京100050

出　　处：《生理科学进展》2008年第3期233-238,共6页Progress in Physiological Sciences

基　　金：教育部长江学者奖励基金资助课题

摘　　要：特发性肺纤维化是严重危害生命的间质性肺疾病,诊断后半数生存率仅为3年,超过大部分恶性肿瘤。目前所有的抗肺纤维化治疗措施疗效甚微。随着对肺纤维化发病分子细胞机制研究的不断深入,已经发现并确认多种抗肺纤维化的新药靶。本文首先概述抗肺纤维化疾病的临床治疗现状、正在临床实验的新药物,然后重点介绍作用于肺泡上皮细胞、成肌纤维细胞或具有抑制血管新生、调节Th1/Th2细胞因子平衡、阻断氧化应激等作用药物治疗肺纤维化疾病的前景。Idiopathic pulmonary fibrosis is a relentlessly progressive and typically fatal interstitial lung disease that harms human life severely. Half of patients diagnosed as idiopathic pulmonary fibrosis live no more than three years. No therapy has been clearly shown to prolong survival. Multiple new targets for pulmonary fibrosis have been indicated based on the researches that uncover the molecular and cellular mechanisms for fibrogenic diseases. In this review, we will summarize the clinical treatment for pulmonary fibrogenic diseases and new drugs with clinic trail, and then review focally the prospects of new drugs for pulmonary fibrogenic diseases that target alveolar epithelia/ cells or myofibroblast, inhibit the angiogenesis, regulate the balance of TH1/TH2 cytokines or block oxide stress.

关 键 词：肺纤维化 药物治疗 复方药 

分 类 号：R575[医药卫生—消化系统]